Active Ingredient(s): Sompacitan-beco
FDA Approved: * August 28, 2020
Pharm Company: * NOVO NORDISK INC
Category: Growth Hormone Treatment

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Sogroya Overview

Somapacitan, sold under the brand name Sogroya, is a growth hormone medication.[3] Somapacitan is a human growth hormone analog.[1] Somapacitan-beco is produced in Escherichia coli by recombinant DNA technology.[1] The most common side effects include: back pain, joint paint, indigestion, a sleep disorder, dizziness, tonsillitis, swelling in the arms or lower legs, vomiting, adrenal insufficiency, hypertension, increase in blood creatine phospho...

Read more Sogroya Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Sogroya Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 10mg/1.5ml
  • Solution: 10mg/1.5ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Sogroya: (2 results)

Sorted by National Drug Code
  • 0169-2030 Sogroya 6.7 mg/ml Subcutaneous Injection, Solution by Novo Nordisk
  • 0169-2035 Sogroya 3.3 mg/ml Subcutaneous Injection, Solution by Novo Nordisk

Other drugs which contain Sompacitan-beco or a similar ingredient: (1 result)